Drug Profile
Research programme: microbiome therapeutics - Johnson and Johnson Consumer/Johnson and Johnson Innovation/Dermala
Latest Information Update: 30 Jun 2022
Price :
$50
*
At a glance
- Originator Dermala; Johnson & Johnson Consumer Companies; Johnson & Johnson Innovation
- Class Bacteria; Skin disorder therapies
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 21 Jun 2022 Dermala has patent protection for microbiome therapeutics in USA
- 28 Feb 2022 No recent reports of development identified for research development in Skin-disorders in USA
- 05 Jan 2018 Johnson and Johnson Innovation, Johnson and Johnson Consumer and Dermala agree to co-develop microbiome therapeutics for Skin disorders